Aptevo CEO Highlights Potential of Multispecific Immunotherapies
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 13 2026
0mins
"Aptevo is entering a defining period as a company, supported by growing clinical momentum, a committed leadership team, and a pipeline with the potential to create significant long-term value," said Jeff Lamothe, President and Chief Executive Officer of Aptevo. "Mipletamig continues to generate compelling frontline AML data, combining strong remission activity with a differentiated safety profile with the potential as an important addition to standard-of-care therapy. At the same time, we are continuing to advance our next generation of multispecific immunotherapy programs, including our emerging trispecific candidates, which are designed to address complex solid tumors through differentiated mechanisms and targeted immune modulation. We believe our ADAPTIR and ADAPTIR-FLEX platforms position Aptevo to expand into multiple high-value areas of oncology innovation. With meaningful clinical and strategic milestones ahead, financial flexibility to support execution, and increasing validation of multispecific approaches throughout the industry, we believe we are building from an increasingly strong foundation for future growth and value creation."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy APVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on APVO
About APVO
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aptevo Reports Strong Data for Mipletamig in AML Treatment
- Significant Clinical Efficacy: Mipletamig, in combination with venetoclax and azacitidine, achieved an 87% clinical benefit rate across 31 evaluable patients, demonstrating broad anti-leukemia activity and blast reduction, surpassing the 66.4% rate observed in the Phase 3 VIALE-A trial.
- Improved Complete Remission Rate: The treatment resulted in a 65% complete remission (CR) rate, significantly higher than the 37% reported in the Phase 3 VIALE-A trial, indicating the potential of this therapy in acute myeloid leukemia treatment.
- Good Safety Profile: No cases of cytokine release syndrome (CRS), a common and often dose-limiting toxicity associated with similar therapies, have been observed in frontline patients to date, highlighting the safety advantage of Mipletamig.
- Strong Financial Position: As of March 31, 2026, Aptevo reported cash and cash equivalents totaling $14.5 million, and raised $0.9 million net in the first quarter of 2026 under Standby Equity Purchase Agreements (SEPAs) with Yorkville, enhancing the company's financial flexibility.
See More
Aptevo Therapeutics Reports FY GAAP EPS of -$87.27
- Financial Performance: Aptevo Therapeutics reported a FY GAAP EPS of -$87.27, indicating significant financial challenges that could negatively impact investor confidence and stock performance.
- Cash Position: As of the end of FY 2025, Aptevo's cash and cash equivalents stood at $21.6 million, a substantial increase from $8.7 million at December 31, 2024, suggesting improved cash management that supports operations into Q4 2026.
- Reverse Stock Split: The company announced a 1-for-18 reverse stock split aimed at boosting its stock price, which may attract more investor interest, although it still faces challenges in achieving profitability in the near term.
- Future Outlook: Despite the current financial difficulties, Aptevo expects its existing resources to sustain operations through Q4 2026, demonstrating resilience and potential for continued operation amid adversity.
See More
Aptevo Therapeutics Announces Executive Changes
- CEO Retirement Announcement: Aptevo Therapeutics' CEO Marvin White will retire on April 1, 2026, transitioning to executive chair, which signifies a major leadership shift that could impact the company's strategic direction and investor confidence.
- New CEO Appointment: Chief Operating Officer Jeff Lamothe will be appointed as the new President and CEO, joining the board, and this appointment is expected to bring fresh management perspectives and operational efficiencies that could drive future growth.
- Board Structure Change: John E. Niederhuber will move from chairman to lead independent director, aiming to enhance corporate governance and improve the board's independence and decision-making capabilities, which may positively influence the company's long-term strategy.
- Reverse Stock Split: Aptevo Therapeutics announced a 1-for-18 reverse stock split, aimed at increasing the share price to improve market perception and attract more investor interest, potentially enhancing the company's financing capabilities.
See More
Aptevo (APVO) Implements 1-for-18 Reverse Stock Split, Reducing Shares to 1 Million
- Reverse Stock Split Plan: Aptevo Therapeutics is set to implement a 1-for-18 reverse stock split on December 29, 2025, reducing outstanding shares from approximately 18 million to about 1 million, aimed at increasing the share price to meet Nasdaq listing requirements.
- Market Reaction: Prior to the reverse split, APVO shares traded between $0.50 and $109.8 over the past year, closing at $0.60, down 34.73% from the previous day, indicating market concerns regarding the company's outlook.
- Historical Split Record: This marks Aptevo's second reverse stock split in 2025, following a 1-for-20 split that took effect on May 27, reflecting the company's ongoing efforts in stock price management.
- Shareholder Impact: The reverse split will automatically convert every 18 shares of common stock into 1 share, while the par value remains at $0.001, significantly reducing shareholders' equity and potentially affecting investor confidence and future fundraising capabilities.
See More
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split, Shares Plunge 38.4%
- Reverse Stock Split Announcement: Aptevo Therapeutics has announced a 1-for-18 reverse stock split effective December 29, converting every 18 shares into one, which has led to a significant 38.4% drop in share price to $0.57, indicating a negative market reaction despite prior shareholder approval in July.
- Severe Market Reaction: Following the reverse stock split announcement, Aptevo's shares plummeted sharply during Friday's session, reflecting investor concerns about the company's future prospects, which could adversely affect its financing capabilities and market confidence.
- Shareholder Approval Context: The final ratio for the reverse split was approved by the board in mid-December, despite having received shareholder support at the July annual meeting, yet the market's response raises questions about the company's governance and strategic direction.
- Industry Impact: The sharp decline in Aptevo's stock price may affect its competitive position in the biopharmaceutical sector, particularly regarding financing and partnership opportunities, as investors may reassess its investment value.
See More
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split, Shares Hit All-Time Low
- Reverse Stock Split Announcement: Aptevo Therapeutics has announced a 1-for-18 reverse stock split effective December 29, converting every 18 shares into one, aimed at boosting share price to meet listing requirements, yet this move has not prevented the stock from hitting an all-time low.
- Shareholder Approval: The reverse split was approved at the annual shareholder meeting in July, with the board confirming the final ratio in mid-December, demonstrating the company's commitment to structural adjustments with shareholder backing.
- Deteriorating Financial Performance: Aptevo recently reported a quarterly loss of $2.23 per share, exceeding analyst expectations of $2.09, with net losses increasing year-over-year from $5.1 million to $7.5 million, indicating heightened financial pressure on the company.
- Stock Price Decline: Following the announcement, Aptevo shares plummeted by 44.08%, trading at $0.5176, positioned at the lower end of its 52-week range, reflecting market pessimism regarding the company's future prospects.
See More
Aptevo Reports Strong Data for Mipletamig in AML Treatment
- Significant Clinical Efficacy: Mipletamig, in combination with venetoclax and azacitidine, achieved an 87% clinical benefit rate across 31 evaluable patients, demonstrating broad anti-leukemia activity and blast reduction, surpassing the 66.4% rate observed in the Phase 3 VIALE-A trial.
- Improved Complete Remission Rate: The treatment resulted in a 65% complete remission (CR) rate, significantly higher than the 37% reported in the Phase 3 VIALE-A trial, indicating the potential of this therapy in acute myeloid leukemia treatment.
- Good Safety Profile: No cases of cytokine release syndrome (CRS), a common and often dose-limiting toxicity associated with similar therapies, have been observed in frontline patients to date, highlighting the safety advantage of Mipletamig.
- Strong Financial Position: As of March 31, 2026, Aptevo reported cash and cash equivalents totaling $14.5 million, and raised $0.9 million net in the first quarter of 2026 under Standby Equity Purchase Agreements (SEPAs) with Yorkville, enhancing the company's financial flexibility.
See More
Aptevo Therapeutics Reports FY GAAP EPS of -$87.27
- Financial Performance: Aptevo Therapeutics reported a FY GAAP EPS of -$87.27, indicating significant financial challenges that could negatively impact investor confidence and stock performance.
- Cash Position: As of the end of FY 2025, Aptevo's cash and cash equivalents stood at $21.6 million, a substantial increase from $8.7 million at December 31, 2024, suggesting improved cash management that supports operations into Q4 2026.
- Reverse Stock Split: The company announced a 1-for-18 reverse stock split aimed at boosting its stock price, which may attract more investor interest, although it still faces challenges in achieving profitability in the near term.
- Future Outlook: Despite the current financial difficulties, Aptevo expects its existing resources to sustain operations through Q4 2026, demonstrating resilience and potential for continued operation amid adversity.
See More
Aptevo Therapeutics Announces Executive Changes
- CEO Retirement Announcement: Aptevo Therapeutics' CEO Marvin White will retire on April 1, 2026, transitioning to executive chair, which signifies a major leadership shift that could impact the company's strategic direction and investor confidence.
- New CEO Appointment: Chief Operating Officer Jeff Lamothe will be appointed as the new President and CEO, joining the board, and this appointment is expected to bring fresh management perspectives and operational efficiencies that could drive future growth.
- Board Structure Change: John E. Niederhuber will move from chairman to lead independent director, aiming to enhance corporate governance and improve the board's independence and decision-making capabilities, which may positively influence the company's long-term strategy.
- Reverse Stock Split: Aptevo Therapeutics announced a 1-for-18 reverse stock split, aimed at increasing the share price to improve market perception and attract more investor interest, potentially enhancing the company's financing capabilities.
See More
Aptevo (APVO) Implements 1-for-18 Reverse Stock Split, Reducing Shares to 1 Million
- Reverse Stock Split Plan: Aptevo Therapeutics is set to implement a 1-for-18 reverse stock split on December 29, 2025, reducing outstanding shares from approximately 18 million to about 1 million, aimed at increasing the share price to meet Nasdaq listing requirements.
- Market Reaction: Prior to the reverse split, APVO shares traded between $0.50 and $109.8 over the past year, closing at $0.60, down 34.73% from the previous day, indicating market concerns regarding the company's outlook.
- Historical Split Record: This marks Aptevo's second reverse stock split in 2025, following a 1-for-20 split that took effect on May 27, reflecting the company's ongoing efforts in stock price management.
- Shareholder Impact: The reverse split will automatically convert every 18 shares of common stock into 1 share, while the par value remains at $0.001, significantly reducing shareholders' equity and potentially affecting investor confidence and future fundraising capabilities.
See More
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split, Shares Plunge 38.4%
- Reverse Stock Split Announcement: Aptevo Therapeutics has announced a 1-for-18 reverse stock split effective December 29, converting every 18 shares into one, which has led to a significant 38.4% drop in share price to $0.57, indicating a negative market reaction despite prior shareholder approval in July.
- Severe Market Reaction: Following the reverse stock split announcement, Aptevo's shares plummeted sharply during Friday's session, reflecting investor concerns about the company's future prospects, which could adversely affect its financing capabilities and market confidence.
- Shareholder Approval Context: The final ratio for the reverse split was approved by the board in mid-December, despite having received shareholder support at the July annual meeting, yet the market's response raises questions about the company's governance and strategic direction.
- Industry Impact: The sharp decline in Aptevo's stock price may affect its competitive position in the biopharmaceutical sector, particularly regarding financing and partnership opportunities, as investors may reassess its investment value.
See More
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split, Shares Hit All-Time Low
- Reverse Stock Split Announcement: Aptevo Therapeutics has announced a 1-for-18 reverse stock split effective December 29, converting every 18 shares into one, aimed at boosting share price to meet listing requirements, yet this move has not prevented the stock from hitting an all-time low.
- Shareholder Approval: The reverse split was approved at the annual shareholder meeting in July, with the board confirming the final ratio in mid-December, demonstrating the company's commitment to structural adjustments with shareholder backing.
- Deteriorating Financial Performance: Aptevo recently reported a quarterly loss of $2.23 per share, exceeding analyst expectations of $2.09, with net losses increasing year-over-year from $5.1 million to $7.5 million, indicating heightened financial pressure on the company.
- Stock Price Decline: Following the announcement, Aptevo shares plummeted by 44.08%, trading at $0.5176, positioned at the lower end of its 52-week range, reflecting market pessimism regarding the company's future prospects.
See More
